Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With COVID-19–Single-Center Experience

Varadarajan, Poovazhagi; Selladurai, Elilarasi; Solomon, Ritchie Sharon; Subramani, Seenivasan; Subramanian, R.; Rangabashyam, Nisha; Srividya, G.

doi:10.1007/s13312-023-2887-0

Cited by 3 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Severe myocardial dysfunction has been reported as a common cardiac abnormality in children with MIS-C [18]. Studies have also reported that coronary abnormalities were seen in 45.9% of MIS-C children, and the majority of cases display left ventricular dysfunction normalized before discharge [19]. A recent study from Poland reported that the majority of children had echocardiographic features of cardiovascular involvement in the course of MIS-C, but the majority of children with acute heart failure improved significantly within a few days of treatment [20].…”

Section: Discussionmentioning

confidence: 99%

Immune Profiles in Multisystem Inflammatory Syndrome in Children with Cardiovascular Abnormalities

Kumar,

Venkataraman,

Nancy

et al. 2023

Viruses

Self Cite

View full text Add to dashboard Cite

Background: Multisystem inflammatory syndrome in children (MIS-C), a sequela of severe acute respiratory syndrome coronavirus-2 infection (SARS-CoV2), has been progressively reported worldwide, with cardiac involvement being a frequent presentation. Although the clinical and immunological characteristics of MIS-C with and without cardiac involvement have been described, the immunological differences between cardiac and non-cardiac MIS-C are not well understood. Methods: The levels of type 1, type 2, type 17, other proinflammatory cytokines and CC chemokines and CXC chemokines were measured using the Magpix multiplex cytokine assay system in MIS-C children with MIS-C cardiac (MIS-C (C) (n = 88)) and MIS-C non-cardiac (MIS-C (NC) (n = 64)) abnormalities. Results: MIS-C children with cardiac manifestations presented with significantly increased levels of cytokines such as IFN-γ, IL-2, TNFα, IL-5, IL-1α, IL-1β, IL-6, IL-10 and IL-12p70 and chemokines such as CCL2, CCL3, CCL11 and CXCL10 in comparison to MIS-C children without cardiac manifestations. Clustering analysis revealed that cytokines and chemokines could clearly distinguish MIS-C children with and without cardiac manifestations. In addition, these responses significantly diminished and normalized 9 months after treatment. Conclusions: This is one of the first studies characterizing and differentiating systemic inflammation in MIS-C with and without cardiac involvement from a low- and middle-income country (LMIC). Our study contributes to the existing body of evidence and advances our knowledge of the immunopathogenesis of MIS-C in children.

show abstract

Section: Discussionmentioning

confidence: 99%

Immune Profiles in Multisystem Inflammatory Syndrome in Children with Cardiovascular Abnormalities

Kumar,

Venkataraman,

Nancy

et al. 2023

Viruses

Self Cite

View full text Add to dashboard Cite

show abstract

Pediatric COVID-19 and MIS-C–Lessons Learnt and the Way Forward

2023

View full text Add to dashboard Cite

Transient erythroblastopenia of childhood after COVID-19 infection: a case report

Rivetti,

Abbate,

Longobardi

et al. 2024

Ital J Pediatr

View full text Add to dashboard Cite

Background Transient erythroblastopenia of childhood (TEC) is an acquired, self-limited pure red cell aplasia that usually occurs in children 4 years old and younger. This clinical condition has been priorly described to be linked to numerous viral and immunologic mechanisms. COVID-19, caused by the coronavirus SARS-CoV-2, was initially discovered in China in December 2019. The disease quickly spread worldwide, resulting in pandemic. Case Presentation This manuscript reports a new clinically relevant condition associated to COVID-19, describing a child with clinical and biochemical signs of Pure Red Blood cells aplasia and complete absence of erythroblasts at the bone marrow needle aspiration with signs of erythrophagocytosis, resembling morphological signs such as in hemophagocytic lymphohistiocytosis (HLH), temporally associated to SARS-CoV-2 infection. Conclusion This report highlights a newly described continuum laboratory and clinical spectrum of immune/hematological dysregulations secondary to SARS-CoV-2. SARS-CoV‐2 infection-linked TEC has never been described in literature, but, according to our findings, should be considered in all the patients with transient erythroblastopenia without congenital red blood cell abnormalities and serology negative for major infections associated with TEC. This condition must be considered in the same spectrum of MIS-C and the inter-links among the two clinical manifestations, as well as a potential interdependence among them, should be considered in the future.

show abstract

Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With COVID-19–Single-Center Experience

Cited by 3 publications

References 15 publications

Immune Profiles in Multisystem Inflammatory Syndrome in Children with Cardiovascular Abnormalities

Immune Profiles in Multisystem Inflammatory Syndrome in Children with Cardiovascular Abnormalities

Pediatric COVID-19 and MIS-C–Lessons Learnt and the Way Forward

Transient erythroblastopenia of childhood after COVID-19 infection: a case report

Contact Info

Product

Resources

About